23 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal … . The Act further provides that: an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose
424B3
ADAP
Adaptimmune Therapeutics Plc
20 Apr 23
Prospectus supplement
4:32pm
, TCR2 and members of their respective boards of directors challenging the merger, and an adverse ruling in any such lawsuit may delay or prevent … of directors challenging the merger, and an adverse ruling in any such lawsuit may delay or prevent the completion of the merger or result in an award
S-4/A
ADAP
Adaptimmune Therapeutics Plc
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
Adaptimmune, TCR2 and members of their respective boards of directors challenging the merger, and an adverse ruling in any such lawsuit may delay … of directors challenging the merger, and an adverse ruling in any such lawsuit may delay or prevent the completion of the merger or result in an award
S-4
fhnw1tn
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-10.01
q13trvr8td x72
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
EX-10.1
2e6hjlymnceplavb
16 Dec 20
Departure of Directors or Certain Officers
5:01pm
8-K
EX-10.1
mhst1 8dc4w
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-10.1
8lh80gyt5t7y
1 Aug 19
New Executive Team Announced at Adaptimmune
7:22am
8-K
EX-10.1
qdaq0ay2
27 Jun 19
Departure of Directors or Certain Officers
8:08am
10-K
EX-10.20
pw1hdy6k8hw8tto2flzs
13 Mar 17
Annual report
12:00am
10-K
1lx5rj qtub9itcd2
13 Mar 17
Annual report
12:00am
10-K
EX-10.18
p7m1d8n 0wj736z32m24
13 Mar 17
Annual report
12:00am